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INTRODUCTION
Matrix Metalloproteinases (MMPs) are zinc-dependent endoproteases central to digestion of extracellular matrix (ECM) and pericellular proteins involved in regulation of many normal physiological processes including tissue growth and embryogenesis. [1] [2] [3] [4] [5] Their activity is regulated by both postsecretion zymogenic activation and inhibition by endogenous inhibitors termed TIMPs (tissue inhibitor of metalloproteinase). 6 However, dysregulation of MMP expression and unbalanced endoproteolytic activity of specific MMPs are a major contributor to many degradative diseases including arthritis, cancer, cardiovascular disease, inflammatory disorders, and neurodegeneration, 5, [7] [8] [9] thus making them attractive drug targets. 2, 10, 11 In the last two decades significant drug discovery effort was focused on inhibition of MMPs as a strategy to prevent tumour invasion and subsequent tumour metastases. 12 As a result the pharmaceutical industry produced a number of well tolerated orally active MMP inhibitors (MMPi). 13 These agents were largely peptidomimetic zinc-binding hydroxamates, based upon an MMP peptide substrate. 2, 14, 15 Although many of these inhibitors progressed to late stage clinical trials against metastatic cancer, limited clinical success was seen due to a lack of inhibitor MMP-subtype specificity and insufficient knowledge about the complexity of the disease biology. 2, 16, 17 Several additional strategies have been evaluated over recent years, including development of inhibitors exploiting the enzymatic transition state, 2, 18 inhibitors binding enzyme cavity subsites, 19 or alternative zinc chelation groups. 2 Generation of MMP subfamily-selective inhibitors still proves mostly elusive however, because of the broad structural similarity of their active site, substrate complexity, and identification of specific MMPs as anti-targets. 2, 17 In contrast to inhibition of MMP function, exploitation of the MMP-mediated proteolysis within diseased tissues has also been investigated as a diagnostic and prognostic approach. These studies used activity-based probes comprising a 'broad-spectrum' or selective MMP-cleavable peptide labelled with a quenched fluorophore or imaging moiety. 20, 21 In this approach, elevated MMP activity in the diseased tissue results in activation of the probe via selective cleavage of the peptide and release of the contrast agent, facilitating imaging and quantification of MMP activity. 20, 21 In line with the MMP-activated probe-based approaches, elevated activity of MMPs within diseased tissue has also been explored as a strategy for conversion of a non-toxic peptideconjugated prodrug into a potent therapeutic entity within the disease site. The advantage of this approach is dose intensification and reduced systemic drug exposure. 1, [22] [23] [24] [25] [26] A requirement for success in activity-probes, prodrugs, or theranostic approaches is MMP-selectivity through incorporation of MMP-subtype unique (e.g. MMP-2, MMP-9 or MMP-14) peptide sequences and subsequent disease-selective activation.
The rationale for this study is to exploit the MMP binding subsites and modify the substrate residues to produce a pro-2 drug selective for MMP-2 over MMP-9 and MMP-14, and create a robust approach which could be exploited for development of endoprotease-activated diagnostic probes and therapeutics. Visualizing and quantifying binding preferences and motifs can provide valuable insight into the structural determinants of substrate selectivity and enable MMP-targeted drug development. 27 In order to achieve this the following steps were undertaken; definition of the catalytic domains within the relevant MMPs through in silico study, docking of known MMP-selective sequences to highlight key catalytic binding determinants, subsequent rational design of novel MMPselective prodrugs, and in vitro confirmation of MMPselectivity and therapeutic proof-of-concept. In this work a reiterative approach using in silico proteolytic docking coupled to in vitro biochemical assessment has been applied to enable the development of prodrugs that are selectively activated by MMP-2 over MMP-9, the closely related gelatinase family members; and over MMP-14 -the endogenous activator of MMP-2. The availability of three-dimensional crystal structures of MMPs allowed us to critically examine the differences existing between the catalytic domains of the MMP-2 (PDB ID: 1QIB), MMP-9 (PDB ID ID: 1GKC) and MMP-14 (PDB ID: 1BQQ). 28, 29, 30 This allowed for successful development of in silico models of MMPs. The in silico model was able to accurately predict known cleavage sites on substrates and prodrugs by MMPs, thus enabling rationalized design of an MMP-2 selective peptide.
RESULTS AND DISCUSSION
The catalytic domain of MMPs consists of five β-sheet strands and three α-helixes. The catalytic centre comprises of a catalytic zinc ion coordinated by three histidine residues and a glutamic acid. 28 The specificity loop within the catalytic site of MMPs shows the largest structural differences, as visualized for MMP-2 and MMP-9 in Figure S1 . The overall folding of MMP-2 and MMP-9 resembles those of other MMPs, which is expected based on their structural similarity ( Figure S1 ). 31 The cavity of S1' pockets in MMPs is well-suited to accommodate a wide-range of hydrophobic residues, with the main functional difference between MMP subtypes lying in this region. In MMP-9, residues 421-423 form the wall of the binding pocket and the specificity loop is formed by the residues 424 -430. Arg424 is present at the bottom of S1' pocket and closes off the end. Arg424 is therefore responsible for making the pocket cavity smaller in MMP-9 than in MMP2 ( Figure S1 ). Whereas in MMP-2, the external wall of the S1' pocket is largely formed by Thr227-Phe232 specificity residues, creating a deeper pocket. These differences can potentially be exploited for rational design of MMP-selective substrates/conjugates.
To probe the selective binding of potential substrates the peptide sequence of the non-specific gelatinase substrate 1 Dnp-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-MeAbz)-NH 2 (M-2055) 32 was input into BIOVIA Discovery Studio 4.0, minimized with respect to its geometry, and then docked into the MMPs. In order to validate modelling work, attempts at crystallization of this and other substrates were undertaken in order to determine the X-ray crystal structure. Crystallization experiments failed to yield suitable crystals for structure determination, therefore only force field (CHARMM) minimized geometries of the substrates were employed throughout this study. Figure 1 shows the interaction of 1 peptide sequence with human MMP-2 and MMP-9. In both MMPs the zinc ion interacts with the Gly and Cys(Me) bond, the known cleavage site according to Bickett et al. 32 MMP-9 is able to bind tightly with the substrate residues compared to MMP-2, as determined by differences in their predicted inter-atomic zinc distances and overall binding energies. The substrate bound MMP-complexes provided crucial insight into the differences in their subsite interactions, as S1 and S3 subsites in MMP-2 demonstrated affinity to accommodate longer side-chains than MMP-9. The charged nature of the S2 subsite (presence of His205) in MMP-2 lends affinity for acidic residues, whereas this feature is not observed in MMP-9. In the MMP-9 structure, the carboxylic acid between Gly and Cys(Me) chelates the zinc ion (2.1 Å) and is involved in a strong H-bond to the carboxylate O of Glu402. The zinc ion is further coordinated by three Histidine residues namely His401, His405 and His411 present in Helix αβ segment of the protein. Only the P1' amino acid is involved in strong H-bonds with Arg424 (2.2 Å), which creates the wall-forming segment. The strong binding of Arg424 with the P1' residue is an important determinant of the specificity pocket. Remaining substrate residues are involved in strong interactions with the bulge-edge segment molecules (Gly186 to His190) with interatomic distances ranging from 2.5 to 3.1 Å. The docked complex of 1 and MMP-9 has an overall binding energy of 706 kcal/mol (Figures 1 ,S2, S3 and S4). Consideration of the interaction of 1 with the active site of MMP-2 shows a marked reduction in affinity in energetic terms, the predicted interaction is seven times weaker than that of 1 and MMP-9 (binding energy of 101 kcal/mol). Gly forms the P1 subsite and Cys(Me) forms the P1' subsite and the presence of a zinc ion, chelated by the carboxylic acid between P1-P1' residues (3.8 Å), further confirms this. The P1' residue, although favourable for the MMP-2 specificity 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  593 pocket, is not involved in any significant interaction with MMP-2 residues. The remaining substrate residues have weak H-bond interactions with wall-forming and bulge-edge segments of MMP-2 with interatomic distances ranging from 3.1 to 5.1 Å. This is expected as 1 residues are oriented away from further MMP-2 binding pockets ( Figure 1 , S2, S3 and S4). Key observed differences between the binding affinity of MMP-2 and MMP-9 with 1 are: S1 and S3 subsites in MMP-2 can accommodate longer side-chains than MMP-9. Charged nature of S2 subsite in MMP-2 has affinity for acidic residues, whereas this feature is not observed in MMP-9. Refer to figure S5 for in silico binding of 1 with the active site of MMP-14, also demonstrating zinc interaction between Gly-Cys(Me) bond.
To experimentally validate the predictability of this model, and confirm the in vitro cleavage position of 1, hydrolysis of the substrate by recombinant MMP-2 and MMP-9 was assessed over a 12 hour period. The resultant products were analysed by LCMS using a reverse phase gradient system to separate the substrate 1 and proteolytic products. The identification of these species was confirmed by retention time and mass spectrometry (MS) data. 1 demonstrated a retention time (tR) of 2.8 minutes ( Figure S6 ) and rapid cleavage by MMP-9 at Gly-Cys(Me) bond was confirmed by LCMS, two peaks corresponding to Dnp-Pro-β-Cyclohexyl-Ala-Gly at tR of 2. The next phase of the study was to design a prodrug (substrate and warhead) which would be selectively activated by a specific MMP over a close family homologue i.e. cleaved by MMP-2 and not by MMP-9 or MMP-14. A known MMPtargeted peptide-conjugated doxorubicin prodrug 33,34 was evaluated as it is cleaved by MMP-2, MMP-9 and MMP-14, presenting an excellent model for further modification. MMPtargeted peptide-conjugates were synthesized via solid phase chemistry and purified by reverse phase HPLC, the chemotherapeutic drug doxorubicin conjugated to the C-terminus (Scheme S10). In silico interaction of the 2 (reference compound) with MMP-2 and MMP-9 shows the zinc ions are chelated by the carboxylate between Gly-Ser(O-Benzyl) bond (2.6 Å and 2.8 Å respectively), the known cleavage site.
31,32 Figure S11 shows the binding pockets of MMP-2 are larger and deeper than MMP-9, S1 subsite allowing for larger aromatic residues. The compound 2 aligns tightly into the active site of both MMPs as shown by their predicted interatomic zinc distances and binding energies (555 kcal/mol and 492 kcal/mol) in MMP-2 and MMP-9 docked complexes respectively. Active site residues interact with the compound in a similar way to that previously explained. His205 in MMP-2 αβ-Helix loop makes the S2 pocket charged in nature and could potentially accommodate acidic residues (Figures S11 and S12). Similar to MMP-2 and MMP-9, MMP-14 also demonstrated selective interaction with 2 ( Figure S13 ) To experimentally validate the in silico docking of 2 33,34 and confirm the in vitro cleavage site, the lysis of this prodrug by recombinant MMP-2 and MMP-9 was assessed over a 12 hour period; with the resultant products being assessed by LCMS. HPLC (reverse phase gradient) was used to separate 2 (CbzGlu-Pro-Leu-Gly-Ser(O-Benzyl)-Tyr-Leu-Doxorubicin), 33, 34 identification confirmed by mass spectrometry (MS) with a retention time (tR) of 3.63 minutes ( Figure S14 Rational design of a peptide conjugate selective for MMP-2 over MMP-9 was achieved by incorporating residues into the peptide chain to fit S1, S2, S3 and S1' pockets of MMP-2 which differ in size and polar affinity compared to MMP-9. The following modifications were incorporated: Aromatic residues in S1 subsite; acidic side-chain in S2 subsite and a polar side-chain at the S3 subsite. Small non-polar residues were included at the S1' subsite despite S1's potential to accommodate longer hydrophobic residues. This was due to longer residues leading to a negative effect on the predicted binding affinity, due to conformational alteration. (Figures S22 and S23) . Conversely MMP-9 and MMP-14 did not cleave 3 in the same timeframe, indicating that 3 is MMP-2 selective supporting the in silico prediction ( Figure S22 and S24) .
In order to assess activity and demonstrate proof-of-concept for the developing approach, the effects of 3 were assessed against the U87-MG malignant human glioma cell line. This cell line is derived from a highly aggressive glioma tumour and expresses both MMP-2 and MMP-9 ( Figure 5 ). Cytotoxicity was observed in this cell line with doxorubicin, Leucinedoxorubicin (Leu-Dox) and 3, with IC50 values of 0.3±0.2 µM, 0.6±0.2 µM and 5.0±1.2 µM, respectively. The differential cytotoxicity between doxorubicin and 3 supports the requirement for 3 to be activated prior to inducing its effects. Furthermore, 3 remained inactive in the presence of a pan-MMP inhibitor, (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2 -yl]-2-(2-methylpropyl)butanediamide (GM6001; Ilomastat/Galardin), 37 demonstrating MMP-selective chemotherapeutic action of this prodrug.
In order to further determine the tumour-selective activation of 3, its metabolism was studied ex vivo using MMPexpressing HT1080 human tumour xenograft 33 , mouse plasma and homogenized murine liver and kidney tissues ( Figure  S25 ). Rapid metabolism of 3 was observed in the HT1080 xenograft homogenate (t ½ = > 8.8 minutes). In comparison, 3 was relatively stable in plasma (t ½ = significantly > 90 minutes), murine liver (t ½ = > 17.0 minutes) and murine kidney (t ½ = > 38.1 minutes). The liver homogenate is a 'worse case scenario' for 3's stability due to a high proportion of both extracelluar and intracellular proteases. 3 displayed relative stability in mouse plasma and liver and kidney homogenates, and associated rapid metabolism in tumour homogenates. 
CONCLUSIONS
Targeted cancer therapies offer the potential of reduced side effects along with benefits of prolonging drug exposure to cancerous tissues, enabling improved tumour response and survival rates. 38, 39 Harnessing the elevated enzymatic activity of MMPs within the tumour microenvironment to selectively convert a non-toxic prodrug into a potent chemotherapeutic agent is one such approach with significant potential therapeutic scope. 40, 41 In this study a reiterative approach using in silico docking coupled to in vitro biochemical proteolytic assessment have been applied to enable the development of anticancer prodrugs selectively activated by MMP-2, but not by close family homologue-MMP-9 or the MMP-2 activator MMP-14. Proof-of-concept for this therapeutic approach was demonstrated against a glioma cell line in vitro, with the involvement of MMPs confirmed using pharmacological inhibition and by tumour-selective activation with ex vivo tumour xenografts. This study has shown that it is feasible to utilise in silico predictive approaches to rationally design MMP-5 selective prodrugs with possible utility in the treatment of cancer.
EXPERIMENTAL

3D-Molecular Modelling Refer to Method S30
Synthesis of MMP-targeted peptide conjugates
Custom designed peptide sequences with Cbz (Benzyloxycarbonyl) as the chemical endcap were supplied (Bachem, Switzerland)/ synthesised using solid phase strategy. Activation of the pre-loaded 2-chlorotrityl resin was carried out in a fritted polypropylene reaction chamber. 0.1mmol of resin was weighed into the reaction chamber and 2 ml of dry DCM added. The reaction vessel was shaken for 45 minutes. After this time, DCM removed and the resin washed further with DCM. Single couplings were carried out using 5 equivalents of peptide (compared to resin), 5 equivalents of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP®), 10 equivalents of N,N-Diisopropylethylamine (DIPEA) and 2 ml of DMF under agitation for 45 minutes. Double peptide couplings were carried out-2 x 45 minute couplings for each residue addition-the reaction drained after each coupling and fresh reagents added. After each set of coupling reactions, the reaction solution was drained and resin washed with 5 portions of 2 ml DMF. Removal of the Fmoc group was carried out using 5 ml of a solution of 20% piperidine in DMF for 5 under agitation. Piperidine solution was drained and fresh solution added for a further 10 minutes under agitation. Piperidine solution was drained and the resin rinsed using 5 portions of 2 ml DMF. Peptide-resin was treated with a solution of 20% hexafluoroisopropanol in DCM for 1 hour. The resin was removed by filtration and the solvent removed from the filtrate under reduced pressure before precipitation using ether and decanting of the liquid (followed by subsequent ether washes). The resulting solid peptide (Cbz-GPIQ(Trt)-E(tBu)-hPhe-L-OH) was dissolved in deionized water and acetonitrile mix and lyophilized. Purification of peptides was carried out using Perking Elmer HPLC. Samples were injected into a column and a gradient of 0-100% solvent B (solvent A= 95% H 2 O, 5% MeCN, 0.01% TFA, solvent B = 95% MeCN, 5%H 2 O, 0.01% TFA) over 95 minutes with a flow rate of 2.0 ml/min. Doxorubicin was conjugated to the peptide C-terminus as follows: Doxorubicin.HCl (0.0012 g, 0.002 mol, 1 equiv.), peptide (0.0022 g, 0.002 mol, 1 equiv.), PyBOP® (0.0015 g, 0.003 mol, 1.3 equiv.), and hydroxybenzotriazole hydrate (0.0073 g, 0.0054 mol, 2.6 equiv.) were added together under nitrogen in anhydrous DMF (2 mL). DIPEA (8 equiv., 0.016 mol) was added and the reaction mixture was stirred overnight in the absence of light. Solvent was removed in vacuo and the mixture triturated with cold Et 2 O (5 mL) to precipitate the crude peptide which was then obtained through centrifugation to obtain the crude solid peptide conjugate. The product was then purified using a C18 column and reverse phase HPLC (H 2 O/MeCN) gradient system using mass spectrometry as confirmation of molecular mass to give a pale red solid (0.0021 g, 70 % yield).
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